
Sarclisa Approved in EU for Treating Transplant-Ineligible Newly Diagnosed Multiple Myeloma
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of…












